A phase I/II study of safety and efficacy of the arginase inhibitor INCB001158 plus chemotherapy in patients (Pts) with advanced biliary tract cancers.

被引：23
|
作者：
Javle, Milind M. [1 ]
Bridgewater, John A. [2 ]
Gbolahan, Olumide B. [3 ]
Jungels, Christiane [4 ]
Cho, May Thet [5 ]
Papadopoulos, Kyriakos P. [6 ]
Thistlethwaite, Fiona C. [7 ,8 ]
Canon, Jean-Luc Re [9 ]
Cheng Lulu [10 ]
Ioannidis, Sonia [10 ]
Gogov, Sven [10 ]
Aung, Naing [11 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] UCL, Inst Canc, London, England
[3] Univ Alabama Birmingham, Birmingham, AL USA
[4] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium
[5] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA
[6] South Texas Accelerated Res Therapeut, San Antonio, TX USA
[7] Dept Med Oncol, Manchester, Lancs, England
[8] Univ Manchester, Christie NHS Fdn Trust, Manchester, Lancs, England
[9] Grand Hop Charleroi, Dept Hematol Oncol, Charleroi, Belgium
[10] Incyte Corp, Wilmington, DE USA
[11] Univ Texas MD Anderson Canc Ctr, Phase Program 1, Dept Invest Canc Therapeut, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期
关键词：
D O I：
10.1200/JCO.2021.39.3_suppl.311
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
311
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I study of the arginase inhibitor INCB001158(1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours
    Naing, A.
    Bauer, T.
    Papadopoulos, K. P.
    Rahma, O.
    Tsai, F.
    Garralda, E.
    Naidoo, J.
    Pai, S.
    Gibson, M. K.
    Rybkin, I.
    Wang, D.
    McDermott, D. F.
    Fasolo, A.
    de Miguel, M.
    Shaheen, M.
    Jenkins, Y.
    Kallender, H.
    Gogov, S.
    Kuriakose, E.
    Pishvaian, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 160 - 160
  • [2] PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study
    Kuboki, Yasutoshi
    Koyama, Takafumi
    Matsubara, Nobuaki
    Naito, Yoichi
    Kondo, Shunsuke
    Harano, Kenichi
    Yonemori, Kan
    Yoh, Kiyotaka
    Gu, Yuan
    Mita, Tetsuya
    Chen, Xuejun
    Ueda, Eiji
    Yamamoto, Noboru
    Doi, Toshihiko
    Shimizu, Toshio
    CANCER MEDICINE, 2024, 13 (08):
  • [3] Updated results from the phase II study: Efficacy and safety of anlotinib plus sintilimab as second-line treatment for patients with advanced biliary tract cancers.
    Jin, Shuiling
    Zhao, Ruihua
    Zhou, Chuang
    Zhong, Qian
    Zhang, Xiaojian
    Zong, Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 577 - 577
  • [4] Phase I/II clinical trial of regorafenib plus durvalumab (MEDI4736) in patients with chemotherapy-refractory advanced biliary tract cancers.
    Al-Rajabi, Raed Moh'd Taiseer
    Kasi, Anup
    Baranda, Joaquina Celebre
    Saeed, Anwaar
    Li, Haoran
    Bruey, Collin
    Best, Shaun
    Phadnis, Milind A.
    Sun, Weijing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS581 - TPS581
  • [5] Phase II study of anlotinib plus sintlimab as second-line treatment for patients with advanced biliary tract cancers.
    Zong Hong
    Zhong Qian
    Zhao Ruihua
    Jin Shuiling
    Zhou Chuang
    Zhang Xiaojian
    Shi Jianxiang
    Qiao Shishi
    Han Jinming
    Jiang Miao
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [6] A phase II study of oxaliplatin (O) and gemcitabine (G) first line chemotherapy in patients with advanced biliary tract cancers.
    Gebbia, N
    Verderame, F
    Di Leo, R
    Santangelo, D
    Cicero, G
    Valerio, MR
    Arcara, C
    Badalamenti, G
    Fulfaro, F
    Carreca, I
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 340S - 340S
  • [7] Efficacy and biomarker analysis of neoadjuvant carrizumab plus apatinib in patients with local advanced biliary tract cancers.
    Rao, Jian-hua
    Wu, Chen
    Zhang, Hui
    Wang, Xuehao
    Lu, Ling
    Cheng, Feng
    Chen, Dongsheng
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Phase II trial of hepatic arterial infusion chemotherapy plus bevacizumab and toripalimab for advanced biliary tract cancers: efficacy, safety, and exploratory analysis
    Zheng, Kanglian
    Fu, Shijie
    Zhu, Xu
    Cao, Guang
    Xu, Liang
    Liu, Peng
    Gao, Song
    Xu, Haifeng
    Guo, Jianhai
    Chen, Hui
    Liu, Wei
    Xu, Da
    Wang, Lijun
    Yan, Xiaoluan
    Bao, Quan
    Wu, Jianhui
    Wang, Kun
    Zhou, Jun
    Hao, Chunyi
    Xing, Baocai
    Shen, Lin
    Yang, Renjie
    Wang, Xiaodong
    HEPATOBILIARY SURGERY AND NUTRITION, 2025,
  • [9] A Phase II Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Biliary Tract Cancers
    Den Linger, Crystal S.
    Meropol, Neal J.
    Li, Tianyu
    Lewis, Nancy L.
    Engstrom, Paul F.
    Weiner, Louis M.
    Cheng, Jonathan D.
    Alpaugh, R. Katherine
    Cooper, Harry
    Wright, John J.
    Cohen, Steven J.
    CLINICAL COLORECTAL CANCER, 2014, 13 (02) : 81 - 86
  • [10] Randomized, multicenter phase II trial of CAP7.1 in patients with advanced biliary tract cancers.
    Pape, Ulrich-Frank
    Kasper, Stefan
    Sinn, Marianne
    Caca, Karel
    Kuhlmann, Jan
    Keilholz, Ulrich
    Vogel, Arndt
    Utku, Nalan
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12345